Get to know the newest members of PGSG!
Visiting Graduate Student
Michela Terlizzi is a PhD student in the Drug Discovery and Development Department in the University of Salerno, Salerno, Italy, where her research focus is on molecular pathways involved in the establishment and progression of cancer. She has recently joined Immaculata De Vivo’s laboratory as a Visiting Graduate Student in the Epidemiology Department at the Harvard T.H. Chan School of Public Health. Michela’s goal is to learn new laboratory techniques and statistical methods to assess genomic instability that may result from exposure to carcinogens. In addition, she would like to understand mechanisms leading to genetic susceptibility of endometrial cancer, as well as all aspects of telomere biology in cancer and longevity.
Steven Gazal, Ph.D.
Steven received his PhD in Public Health from Paris-Sud University in 2014. His research focused on the development of statistical methods estimating inbreeding from dense genotype data, and their application to find recessive effects in multifactorial diseases. During his PhD, Steven was also a research statistician for the genetic platform of the North Paris hospitals where he collaborated with several geneticists on a wide range of research projects.
Steven joined Alkes Price’s lab as a postdoctoral fellow in October 2015. His research will focus on the heritability of complex traits. He is interested in combining population genetics and genetic epidemiology methods in order to understand the genetic basis of human disease.
Kathryn L. Penney, Sc.D.
Assistant Professor of Medicine
Research Associate, Epidemiology
Dr. Penney is an Assistant Professor at the Channing Division of Network Medicine, Brigham and Women’s Hospital, and a Research Associate at the Harvard T.H. Chan School of Public Health. Her research focuses on the molecular and genetic epidemiology of prostate cancer. Her previous publications include a genome-wide association study specifically for lethal prostate cancer, an examination of the relationship between known prostate cancer genetic risk variants and prostate tissue gene expression levels, and the development of a gene expression signature of Gleason grade. She is currently interested in combining various types of biological data, including genetics, gene expression, and metabolomics, to create a more comprehensive picture of prostate cancer aggressiveness.
Timothy R. Rebbeck, Ph.D.
Professor of Epidemiology
Dr. Rebbeck is Professor of Epidemiology at the Dana Farber Cancer Institute and the Harvard T.H. Chan School of Public Health. He leads molecular epidemiology studies of cancer etiology, outcomes, health disparities, and global health. His work has led to an understanding of the genetic and environmental causes of cancer risk, outcomes, and disparities. He currently leads international cancer consortia that study risk and outcomes of 1) cancer in BRCA1/BRCA2 mutation carriers, and 2) prostate cancer in men of African descent in North America, the Caribbean, and Africa.
Dr. Evan Busch
Evan received his PhD in Epidemiology in May 2015 from the University of North Carolina at Chapel Hill, where he worked on the use of markers of epithelial-mesenchymal transition to improve the accuracy of cancer staging. He joined the De Vivo Lab as a postdoctoral fellow in Summer 2015. His research will focus on refining molecular subtypes of endometrial cancer. He is interested in molecular and genetic cancer epidemiology as well as epidemiologic methods.
Dr. Lori Chibnik
Dr. Lori Chibnik, PhD, MPH, is an Assistant Professor of Neurology at HMS and Brigham and Women’s Hospital, with a secondary appointment in HSPH-Epidemiology. Her research focuses on genetics and epigenetics of Alzheimer’s disease, cognitive decline, and multiple sclerosis; and longitudinal data analysis and risk prediction. She and Peter Kraft co-teach EPI 215: Advanced Topics in Case-Control & Cohort Studies (aka “Big data for Epidemiologists”) in the Fall semester. Dr. Chibnik also developed and leads an interactive biostatistics course at the KwaZulu-Natal Research Institute for Tuberculosis and HIV in Durban, South Africa.